Ensuring patient accessRare diseases - Haematology - Lymphoma

Responsible for marketing of extended range of products (on-Patent, off-Patent, and Generics) in various stages in product life cycle (Pre-Launch, Mature and Loss of Exclusivity). Focused on opioid analgesics & antiemetics and launched Lenalidomide in Multiple Myeloma.Responsible for Patient Support Programs (PSP) and communication with Patient Organizations

Reporting to Commercial Director, managed a team of 10 employees- Led Anti-infective & Immunology portfolio through Commercial Excellence transformation for target specialties (Intensive Care, Hematology, Infectious Diseases, Nephrology/Hepatology, Transplantation)- Drove omnichannel customer engagement through launch of 4 new communication channels (Webinars, remote detailing, emailing, web-portal)- Led prelaunch team of hematology product (orphan indication) with challenging M. Access approach - Ensured multifunctional cooperation to Brand strategy aligning Commercial, M. Access & Medical- Served as Certified on-line facilitator on Multichannel engagement, Team Leadership and Change management for Sales Managers in the east European region Selected Achievements:- Maintained market leadership for 9 years, even after genericization of main competitors- Acknowledged as leading affiliate in EMEA for Digital Transformation - Successfully negotiated a price increase with Cypriot authorities for immunology product

Reporting to General Manager, managed a team of 12 employees- Led sales & marketing of portfolio, launched 2nd novel antibiotic, while targeting Intensive Care Units, Hematology, Infection specialists, Transplantation Nephrology/Hepatology- Pioneered digital e-detailing with interactive animated content in Astellas EMEA- Ensured compliance in BU and collaborated in all initiatives for companywide compliance- Planned major salesforce restructuring & identified talent in sales management- Managed relationships with Key Experts, patient associations and selected governmental bodies- Full Astellas portfolio responsibility for Cyprus, launching 4 products in tender and private market; Managed local distributor and represented Astellas in Cypriot Union of Pharma companies (ΚΕFΕΑ) Selected Achievements: - Honorary membership in regional strategy development team, as the only affiliate to achieve market leadership. Influenced corporate strategy by proposing re-targeting opportunity in EU level- No1 in sales among EMEA affiliates for 6 consecutive years for antifungal- Financial award received from Astellas EMEA for exemplary performance

Reporting to General Manager, managed a team of 6 employees- Established the Business Unit structure in the company with responsibility for both sales & marketing. Launched 1st novel antibiotic and penetrated an unknown market.- Established Key Account Management. Recruited, Inspired & coached the KAM team to this holistic approach towards multiple account stakeholders Selected Achievements:- No1 Pan European Astellas Affiliate Award for antinfectives (FY2010 & FY2011)

Reporting to Commercial Director- Responsible for immunology handover from local distributor (Vianex) and successful re-launch Selected Achievements:- 130% sales increase in established immunosuppressant vs 2007 budget

Reporting to Commercial Director Selected Achievements:- Achieved 60% growth for CCB antihypertensive and launched successfully community antibiotic

Reporting to Business Unit Manager- Launched Interferon Product for Hepatitis C. Responsible for National Hepato-Gastroenterology market

- Conducted Granted Research projects in biomedical engineering & authored respective publications- Lectured undergraduate and graduate courses and supervised 3 diploma theses